IDH1 and astrocytoma (excluding glioblastoma): Comparisons of revised classification between PRAME-negative and PRAME-positive cohorts showed that IDH-mutant astrocytoma, grade 2 (26.5% vs. 13.1%) and oligodendroglioma (35.9% vs. 21.7%) dominated PRAME-negative glioma while the incidence of IDH-wildtype glioblastoma, grade 4 (32.9% vs. 4.1%) was much higher in PRAME-positive glioma.